Processa Pharmaceuticals Inc (PCSA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.81M
Last updated: Nov 17, 2026 at 4:10 PM ET
Processa Pharmaceuticals Inc (PCSA) Statistics
Processa Pharmaceuticals (PCSA) has a market cap of $4.81M. It holds $180.21M more cash than debt, 3744.13% of its market cap. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
| Market Cap | $4.81M |
|---|---|
| Latest price (Nov 17, 2026) | $1.73 |
Key Dates
The next earnings report is expected on Mar 16, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 16, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 76.93% over 52 weeks and trades 3.35% below its 50-day average.
| Beta (1Y) | 1.15 |
|---|---|
| 52-Week Change | -76.93% |
| 3-Month Change | -19.53% |
| 6-Month Change | -33.72% |
| 5-Year Change | -99.95% |
| Total Return (1Y) | -76.93% |
| Total Return (3Y CAGR) | -79.95% |
| Total Return (5Y CAGR) | -77.25% |
| Return vs SPY (1Y) | -88.94% |
| Max Drawdown (1Y) | -82.35% |
| Max Drawdown (3Y) | -99.68% |
| Sharpe Ratio (1Y) | -0.94 |
| Correlation with SPY (1Y) | 0.10 |
| 50-Day Average | $1.79 |
| 200-Day Average | $2.28 |
| 52-Week Range | $1.04 to $8.88 |
| RSI (14 Days) | 43.5 |
| Average Volume (20 Days) | 27.12K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 97.70x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 97.70x |
|---|---|
| Quick Ratio | 97.70x |
| Debt / Equity | 0.00x |
Scores
PCSA has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$301 |
| Operating Income | -$193.50M |
| Pretax Income | -$193.09M |
| Net Income | -$193.16M |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $180.21M |
|---|---|
| Total Debt | $0 |
| Net Cash | $180.21M |
| Net Cash Per Share | $60.59 |
| Working Capital | $180.15M |
| Shareholder Equity | -$181.38M |
| Total Assets | $182.01M |
| Total Liabilities | $1.86M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$13.66M |
|---|---|
| FCF Per Share | -$4.88 |
| Depreciation and Amortization | $1.30K |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
PCSA does not pay a dividend.
| Buyback Yield | -3706.01% |
|---|---|
| Shareholder Yield | -3706.01% |
Stock Splits
The last split was a 1-for-25 reverse split on Dec 17, 2025.
| Last Split Date | Dec 17, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:25 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About PCSA
What is PCSA's market cap?
Processa Pharmaceuticals has a market cap of $4.81M.
How many shares of PCSA are outstanding?
Processa Pharmaceuticals has 2.97M shares outstanding.
Does PCSA pay a dividend?
No. Processa Pharmaceuticals does not pay a dividend.
How much debt does PCSA have?
Processa Pharmaceuticals has $0 of total debt and $180.21M of cash and equivalents, a net cash position of $180.21M.
PCSA pages: Overview, Charting, Earnings, Financials, Statistics, Competitors